Stock Detail
SALIX PHARMACEUTICALS LTD
Sector: Drug Related Products
Latest Quote @ Sat May 5 09:01:51 (15 min delayed)
| N/A |
N/A |
$60.39 |
+0.70 |
1.17% |
|
Last Day's Data
| $60.39 |
$60.85 |
$0.70 |
1.17% |
0.00 |
$59.69 |
| $59.70 |
$59.50 |
490,474.00 |
3.70B |
487,089.00 |
49.60 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 61.60 |
61.00 |
60.25 |
59.65 |
58.90 |
Stock Profile
Salix Pharmaceuticals, Ltd. engages in the acquisition, development, and commercialization of prescription drugs used in the treatment of various gastrointestinal diseases, which are those affecting the digestive tract. It offers Colazal Capsules for the treatment of ulcerative colitis; Xifaxan, a gastrointestinal-specific oral antibiotic, for the treatment of patients twelve years of age and older with travelers' diarrhea caused by noninvasive strains of E coli; and Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. The company also offers Anusol-HC and Proctocort cream products, which are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions. The company was co-founded Randy w. Hamilton and lorin k. Johnson. Salix Pharmaceuticals is headquartered in Morrisville, North Carolina.
